



April 22, 2021

## **DAS Therapeutics Begins Phase II Clinical Trial Enrollment for DAS-001, its Medicine for Treatment of Myasthenia Gravis**

BOSTON, MA April 22, 2021 - DAS Therapeutics, Inc. (“DAS” or “the Company”), is pleased to announce enrollment for a Phase II myasthenia gravis clinical trial evaluating DAS-001, a proposed fixed-dose combination tablet that combines the gold standard first-line treatment, pyridostigmine, with an antagonist of the gastrointestinal side effects of pyridostigmine. Myasthenia gravis is a debilitating, chronic autoimmune disease of the neuromuscular junction affecting a person’s skeletal (voluntary) muscles and ability to function. Pyridostigmine, a common symptomatic treatment option, may cause gastrointestinal side effects that lead to significant tolerability issues.

“I am thrilled to be leading this important study to determine if debilitating gastro-intestinal side effects of pyridostigmine can be mitigated”, said Henry Kaminski, MD, Principal Investigator and Chair of the Department of Neurology at the George Washington University School of Medicine and Health Sciences.

“Today represents a big step forward for DAS Therapeutics and the patients that are fighting this life altering disease. We are very fortunate to be able to partner with Dr. Kaminski, an internationally recognized expert in myasthenia gravis and one of the most prominent myasthenia gravis research clinicians in the United States” said Dr. Christina Smith, PharmD, Chief Scientific Officer and Co-Founder of DAS.

The Phase II segment of the trial is designed to evaluate the safety and tolerability of pyridostigmine when given with ondansetron to subjects with anti-AchR positive myasthenia gravis and pyridostigmine-related gastrointestinal side effects. For more information about the clinical trial, see [www.clinicaltrials.gov](http://www.clinicaltrials.gov), identifier NCT04226170 or <https://www.gwdocs.com/research/details/?trial=1382>

### **About DAS Therapeutics**

DAS Therapeutics is a privately funded clinical stage pharmaceutical company. The mission of DAS is to identify, acquire and develop unique assets for conditions overlooked or under-served by current treatment approaches to improve patient outcomes. To learn more visit [www.das therapeutics.com](http://www.das therapeutics.com)

### **Investor Contact**

[inforequest@das therapeutics.com](mailto:inforequest@das therapeutics.com)